Title
Description 
An advertisement for TussiCaps a pharmaceutical company. It features three bottles of different sizes and shapes. On the left side of the image there is an ancient Greek vase with a red and black design. The vase has a handle and a spout and it appears to be made of clay or porcelain. Next to it there are two smaller bottles one with a cork stopper and the other with a label that reads "The less things change. The more dosing habits stay the same."
On the right side of this image on the bottom right corner is a small yellow pill. The text on the image reads "Introducing TussiCaps. The efficacy of syrup with evolved dosing control." The background is a light blue color and the text is in black.
Type
Category
Source 1 of 22
-
Date
2009
Collection
-
Date
2009
Collection
-
Date
2009
Collection
-
Date
2008
Collection
-
Date
2009
Collection
-
Date
2009
Collection
-
Date
2008
Collection
-
Date
2009
Collection
-
Date
2009
Collection
-
Date
2008
Collection
-
Date
2009
Collection
-
Date
2009
Collection
-
Date
2009
Collection
-
Date
2009
Collection
-
Date
2009
Collection
-
Date
2009
Collection
-
Date
2008
Collection
-
Date
2008
Collection
-
Date
2008
Collection
-
Date
2008
Collection
-
Date
2009
Collection
-
Date
2009
Collection
We encourage you to view the image in the context of its source document(s) and cite the source(s) when using these images. However, to cite just this image alone, click the “Cite This Image” button and then paste the copied text.
![A screenshot from the Exalgo website. It appears to show case studies for how to convert different example patients to Exalgo step-by-step. The website is of example patient Dennis and the "Dose Conversion" step is selected. The website has a blue and white color scheme with a blue header and black footer.<br /><br />The main text of the page reads "Exalgo could give Dennis the pain relief he wants - with a once-daily dose. Double-blind placebo-controlled withdrawal study of opioid-tolerant patients with low back pain (447 enrolled 268 randomized; 66[49%] EXALGO patients and 44 [31%) placebo patients completed the study". Below that there is additional text that reads "Conversion/Titration Phase: EXALGO reduced mean pain intensity (NRS*) by 50% in successfully converted patients". <br /><br />The bottom of the page also has indication and important risk information. In the lower right corner there is an image of a person walking a dog on a leash with a tree in the background. The footer has the Exalgo logo and a navigation menu.](https://oida-resources-images.azureedge.net/public/full/788d6c94-1a49-4186-9b61-4e458d11f420.png)
